Warning! GuruFocus detected
1 Severe warning sign
with ADMA.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
ADMA Biologics Inc
NAICS : 325412
SIC : 2834
ISIN : US0008991046
Share Class Description:
ADMA: Ordinary SharesCompare
Compare
Traded in other countries / regions
ADMA.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2013-10-17Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.26 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | 0.56 | |||||
| Interest Coverage | 9.98 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 22.29 | |||||
| Beneish M-Score | 1.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 44.6 | |||||
| 3-Year Book Growth Rate | 26.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 16.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 22.13 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.28 | |||||
| 9-Day RSI | 65.85 | |||||
| 14-Day RSI | 64.65 | |||||
| 3-1 Month Momentum % | -6.07 | |||||
| 6-1 Month Momentum % | -15.45 | |||||
| 12-1 Month Momentum % | 148.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.97 | |||||
| Quick Ratio | 2.9 | |||||
| Cash Ratio | 1.86 | |||||
| Days Inventory | 307.83 | |||||
| Days Sales Outstanding | 35.48 | |||||
| Days Payable | 29.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | 0.65 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.48 | |||||
| Operating Margin % | 32.59 | |||||
| Net Margin % | 46.35 | |||||
| FCF Margin % | 25.82 | |||||
| ROE % | 93.41 | |||||
| ROA % | 51.06 | |||||
| ROIC % | 81.91 | |||||
| 3-Year ROIIC % | 202.61 | |||||
| ROC (Joel Greenblatt) % | 58.79 | |||||
| ROCE % | 41.36 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.71 | |||||
| Forward PE Ratio | 28.53 | |||||
| PE Ratio without NRI | 24.71 | |||||
| Price-to-Owner-Earnings | 27.98 | |||||
| PS Ratio | 11.56 | |||||
| PB Ratio | 13.74 | |||||
| Price-to-Tangible-Book | 13.88 | |||||
| Price-to-Free-Cash-Flow | 45.12 | |||||
| Price-to-Operating-Cash-Flow | 41.95 | |||||
| EV-to-EBIT | 34.36 | |||||
| EV-to-EBITDA | 32.49 | |||||
| EV-to-Revenue | 11.25 | |||||
| EV-to-Forward-Revenue | 7.69 | |||||
| EV-to-FCF | 43.58 | |||||
| Price-to-GF-Value | 2.44 | |||||
| Price-to-Median-PS-Value | 2.11 | |||||
| Price-to-Graham-Number | 3.9 | |||||
| Price-to-Net-Current-Asset-Value | 25.01 | |||||
| Earnings Yield (Greenblatt) % | 2.91 | |||||
| FCF Yield % | 2.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ADMA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ADMA Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 426.454 | ||
| EPS (TTM) ($) | 0.82 | ||
| Beta | 1.05 | ||
| 3-Year Sharpe Ratio | 1.7 | ||
| 3-Year Sortino Ratio | 4.64 | ||
| Volatility % | 70.53 | ||
| 14-Day RSI | 64.65 | ||
| 14-Day ATR ($) | 0.951849 | ||
| 20-Day SMA ($) | 18.38 | ||
| 12-1 Month Momentum % | 148.33 | ||
| 52-Week Range ($) | 5.895 - 23.64 | ||
| Shares Outstanding (Mil) | 237.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ADMA Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ADMA Biologics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ADMA Biologics Inc Frequently Asked Questions
What is ADMA Biologics Inc(ADMA)'s stock price today?
The current price of ADMA is $20.26. The 52 week high of ADMA is $23.64 and 52 week low is $5.90.
When is next earnings date of ADMA Biologics Inc(ADMA)?
The next earnings date of ADMA Biologics Inc(ADMA) is 2025-05-09 Est..
Does ADMA Biologics Inc(ADMA) pay dividends? If so, how much?
ADMA Biologics Inc(ADMA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers